Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+67.7%
5Y CAGR+32.2%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+67.7%/yr
vs -12.6%/yr prior
5Y CAGR
+32.2%/yr
Recent acceleration
Acceleration
+80.3pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
4x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$172.41M+89.7%
2024$90.89M+117.7%
2023$41.76M+14.3%
2022$36.53M-27.6%
2021$50.47M+18.3%
2020$42.65M+83.7%
2019$23.21M-62.8%
2018$62.46M+16.3%
2017$53.69M-5.7%
2016$56.91M-